Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner

A. Zingone, J. Seidel, L. Aloj, C. Caraco, J. J. Vaquero, E. M. Jagoda, J. Y. Chou, M. V. Green, W. C. Eckelman

Research output: Contribution to journalArticle

Abstract

Monitoring gene therapy of glycogen storage disease type 1a in a mouse model was achieved using [18F]FDG and a dedicated animal scanner. The G6Pase knockout (KO) mice were compared to the same mice after infusion with a recombinant adenovirus containing the murine G6Pase gene (Ad-mG6Pase). Serial images of the same mouse before and after therapy were obtained and compared with wild-type (WT) mice of the same strain to determine the uptake and retention of [18F]FDG in the liver. Image data were acquired from heart, blood pool and liver for twenty minutes after injection of [18F]FDG. The retention of [18F]FDG was lower for the WT mice compared to the KO mice. The mice treated with adenovirus-mediated gene therapy had retention similar to that found in age-matched WT mice. These studies show that FDG can be used to monitor the G6Pase concentration in liver of WT mice as compared to G6Pase KO mice. In these mice, gene therapy returned the liver function to that found in age matched WT controls as measured by the FDG kinetics in the liver compared to that found in age matched wild type controls.

Original languageEnglish
Pages (from-to)1293-1301
Number of pages9
JournalLife Sciences
Volume71
Issue number11
DOIs
Publication statusPublished - Aug 2 2002

Fingerprint

Glycogen Storage Disease
Fluorodeoxyglucose F18
Glycogen
Liver
Animals
Gene therapy
Monitoring
Knockout Mice
Genetic Therapy
Adenoviridae
Blood
Genes
Kinetics

Keywords

  • [F]FDG
  • G6Pase
  • Glycogen storage disease type 1a
  • Mouse

ASJC Scopus subject areas

  • Pharmacology

Cite this

Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner. / Zingone, A.; Seidel, J.; Aloj, L.; Caraco, C.; Vaquero, J. J.; Jagoda, E. M.; Chou, J. Y.; Green, M. V.; Eckelman, W. C.

In: Life Sciences, Vol. 71, No. 11, 02.08.2002, p. 1293-1301.

Research output: Contribution to journalArticle

Zingone, A. ; Seidel, J. ; Aloj, L. ; Caraco, C. ; Vaquero, J. J. ; Jagoda, E. M. ; Chou, J. Y. ; Green, M. V. ; Eckelman, W. C. / Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner. In: Life Sciences. 2002 ; Vol. 71, No. 11. pp. 1293-1301.
@article{e9d8d2e1742b4f8788b05073b7c6f9fc,
title = "Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner",
abstract = "Monitoring gene therapy of glycogen storage disease type 1a in a mouse model was achieved using [18F]FDG and a dedicated animal scanner. The G6Pase knockout (KO) mice were compared to the same mice after infusion with a recombinant adenovirus containing the murine G6Pase gene (Ad-mG6Pase). Serial images of the same mouse before and after therapy were obtained and compared with wild-type (WT) mice of the same strain to determine the uptake and retention of [18F]FDG in the liver. Image data were acquired from heart, blood pool and liver for twenty minutes after injection of [18F]FDG. The retention of [18F]FDG was lower for the WT mice compared to the KO mice. The mice treated with adenovirus-mediated gene therapy had retention similar to that found in age-matched WT mice. These studies show that FDG can be used to monitor the G6Pase concentration in liver of WT mice as compared to G6Pase KO mice. In these mice, gene therapy returned the liver function to that found in age matched WT controls as measured by the FDG kinetics in the liver compared to that found in age matched wild type controls.",
keywords = "[F]FDG, G6Pase, Glycogen storage disease type 1a, Mouse",
author = "A. Zingone and J. Seidel and L. Aloj and C. Caraco and Vaquero, {J. J.} and Jagoda, {E. M.} and Chou, {J. Y.} and Green, {M. V.} and Eckelman, {W. C.}",
year = "2002",
month = "8",
day = "2",
doi = "10.1016/S0024-3205(02)01831-3",
language = "English",
volume = "71",
pages = "1293--1301",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner

AU - Zingone, A.

AU - Seidel, J.

AU - Aloj, L.

AU - Caraco, C.

AU - Vaquero, J. J.

AU - Jagoda, E. M.

AU - Chou, J. Y.

AU - Green, M. V.

AU - Eckelman, W. C.

PY - 2002/8/2

Y1 - 2002/8/2

N2 - Monitoring gene therapy of glycogen storage disease type 1a in a mouse model was achieved using [18F]FDG and a dedicated animal scanner. The G6Pase knockout (KO) mice were compared to the same mice after infusion with a recombinant adenovirus containing the murine G6Pase gene (Ad-mG6Pase). Serial images of the same mouse before and after therapy were obtained and compared with wild-type (WT) mice of the same strain to determine the uptake and retention of [18F]FDG in the liver. Image data were acquired from heart, blood pool and liver for twenty minutes after injection of [18F]FDG. The retention of [18F]FDG was lower for the WT mice compared to the KO mice. The mice treated with adenovirus-mediated gene therapy had retention similar to that found in age-matched WT mice. These studies show that FDG can be used to monitor the G6Pase concentration in liver of WT mice as compared to G6Pase KO mice. In these mice, gene therapy returned the liver function to that found in age matched WT controls as measured by the FDG kinetics in the liver compared to that found in age matched wild type controls.

AB - Monitoring gene therapy of glycogen storage disease type 1a in a mouse model was achieved using [18F]FDG and a dedicated animal scanner. The G6Pase knockout (KO) mice were compared to the same mice after infusion with a recombinant adenovirus containing the murine G6Pase gene (Ad-mG6Pase). Serial images of the same mouse before and after therapy were obtained and compared with wild-type (WT) mice of the same strain to determine the uptake and retention of [18F]FDG in the liver. Image data were acquired from heart, blood pool and liver for twenty minutes after injection of [18F]FDG. The retention of [18F]FDG was lower for the WT mice compared to the KO mice. The mice treated with adenovirus-mediated gene therapy had retention similar to that found in age-matched WT mice. These studies show that FDG can be used to monitor the G6Pase concentration in liver of WT mice as compared to G6Pase KO mice. In these mice, gene therapy returned the liver function to that found in age matched WT controls as measured by the FDG kinetics in the liver compared to that found in age matched wild type controls.

KW - [F]FDG

KW - G6Pase

KW - Glycogen storage disease type 1a

KW - Mouse

UR - http://www.scopus.com/inward/record.url?scp=0037008385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037008385&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(02)01831-3

DO - 10.1016/S0024-3205(02)01831-3

M3 - Article

C2 - 12106594

AN - SCOPUS:0037008385

VL - 71

SP - 1293

EP - 1301

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 11

ER -